New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
10:07 EDTRTRX, QCORRetrophin CEO says suit filed against Questcor
On his official Twitter account, Martin Shkreli, ūthe CEO of Retrophin (RTRX), announced his company filed an antitrust lawsuit against Questcor (QCOR) in California last night. Shares of Questcor are down 5% to $50.46 in early trading. Reference Link
News For RTRX;QCOR From The Last 14 Days
Check below for free stories on RTRX;QCOR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
06:08 EDTQCORQuestcor implied volatility of 28 at lower end of index mean range
Subscribe for More Information
August 14, 2014
17:21 EDTQCORGulfMark Offshore to replace Questcor in S&P 600 as of 8/18 close
17:16 EDTQCORPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:35 EDTQCORMallinckrodt completes acquisition of Questcor Pharmaceuticals
Subscribe for More Information
13:02 EDTQCORMallinckrodt, Questcor holders approve Mallinckrodt's acquisition of Questcor
Subscribe for More Information
August 12, 2014
07:03 EDTRTRXRetrophin sees FY15 EPS 75c-$1.25
Sees FY15 revenue $60M-$70M, one estimate $63M.
07:02 EDTRTRXRetrophin sees FY14 revenue $30M-$35M, one estimate $31M
Subscribe for More Information
07:02 EDTRTRXRetrophin reports Q2 EPS 52c vs. 21clast year
Reports Q2 revenue $5.74M, may not compare to one estimate $3.10M.
August 11, 2014
15:39 EDTRTRXRetrophin CEO says 'stay tuned' for financial results in morning
Martin Shkreli, the CEO of Retrophin, stated on Twitter: "we report financial results tomorrow morning. stay tuned!" Reference Link
08:22 EDTRTRXRetrophin CEO in scandal over Twitter use, TheStreet reports
Retrophin has placed the company's social media activity on "lockdown" following questionable tweets from CEO Martin Shkreli, including one that seemed to hint at a Retrophin acquisition of an approved drug from a private company, reported TheStreet's Adam Feuerstein. The social media blackout also follows the discovery that employees were using Twitter aliases to promote Retrophin and pitch short-sale recommendations of other stocks, including a tweet that singled out TherapeuticsMD (TXMD), the report added. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use